List of Excipients in Branded Drug SORAFENIB TOSYLATE

Generic Drugs Containing SORAFENIB TOSYLATE

Company	Ingredient	NDC	Excipient
Mylan Pharmaceuticals Inc	sorafenib	0378-1201	CARBOXYMETHYLCELLULOSE CALCIUM
Mylan Pharmaceuticals Inc	sorafenib	0378-1201	CROSCARMELLOSE SODIUM
Mylan Pharmaceuticals Inc	sorafenib	0378-1201	FERRIC OXIDE RED
Mylan Pharmaceuticals Inc	sorafenib	0378-1201	HYPROMELLOSE 2910
Mylan Pharmaceuticals Inc	sorafenib	0378-1201	MAGNESIUM STEARATE
Mylan Pharmaceuticals Inc	sorafenib	0378-1201	MICROCRYSTALLINE CELLULOSE 101
Mylan Pharmaceuticals Inc	sorafenib	0378-1201	POLYETHYLENE GLYCOL 4000

What are the Most Frequently-Used Excipients in SORAFENIB TOSYLATE?

# Of NDCs	Excipient
1	CARBOXYMETHYLCELLULOSE CALCIUM
1	CROSCARMELLOSE SODIUM
1	FERRIC OXIDE RED
1	HYPROMELLOSE 2910
1	MAGNESIUM STEARATE
1	MICROCRYSTALLINE CELLULOSE 101
1	POLYETHYLENE GLYCOL 4000

Sorafenib Tosylate Excipient Strategy and Commercial Opportunities

Last updated: September 5, 2026

Sorafenib tosylate is a poorly soluble, high-dose oral kinase inhibitor whose commercial value is concentrated in bioequivalent generics, improved dissolution systems, regional supply, and differentiated formulations. The reference product, Nexavar, uses a conventional immediate-release film-coated tablet with microcrystalline cellulose, croscarmellose sodium, hypromellose, sodium lauryl sulfate, magnesium stearate and standard film-coating agents. The strongest excipient opportunities are low-risk dissolution optimization, manufacturability improvements, and formulation platforms that support regulatory differentiation without creating a new clinical-development burden.

What is sorafenib tosylate and how is it administered?

Sorafenib tosylate is the tosylate salt of sorafenib, a multikinase inhibitor targeting RAF kinases, VEGFR, PDGFR and related signaling pathways. FDA-approved indications include unresectable hepatocellular carcinoma, advanced renal cell carcinoma and radioactive iodine-refractory differentiated thyroid carcinoma (FDA, 2024a).

Attribute	Sorafenib tosylate
Reference product	Nexavar
Originator	Bayer and Onyx Pharmaceuticals
Dosage form	Immediate-release film-coated tablet
Strength	200 mg sorafenib tosylate per tablet
Standard adult regimen	400 mg twice daily
Administration	Without food, or with a low- or moderate-fat meal
Key formulation issue	Low aqueous solubility and dissolution sensitivity
Primary regulatory route for generics	ANDA under section 505(j)
Main commercial markets	Oncology, hospital supply, specialty pharmacy and tender markets

The standard daily dose is 800 mg, creating a substantial excipient burden compared with many targeted oral medicines. A formulation that improves dissolution without increasing tablet size, friability or manufacturing complexity has practical commercial value.

What excipients are used in Nexavar and generic sorafenib tablets?

The Nexavar tablet uses a conventional excipient architecture designed for compression, disintegration, wetting and film coating.

Excipient	Primary function	Strategic relevance
Microcrystalline cellulose	Diluent and compression aid	Supports tablet hardness and processability
Croscarmellose sodium	Superdisintegrant	Promotes rapid tablet breakup
Sodium lauryl sulfate	Wetting agent and surfactant	Supports wetting of poorly soluble sorafenib particles
Hypromellose	Binder and film former	Controls granule and coating performance
Magnesium stearate	Lubricant	Reduces tooling friction; excessive use can slow dissolution
Titanium dioxide	Opacifier and colorant	Supports coating appearance and light protection
Red ferric oxide	Colorant	Provides product identification
Polyethylene glycol	Plasticizer in coating	Improves coating flexibility

The inactive ingredients are identified in the FDA prescribing information for Nexavar and in approved generic labeling (FDA, 2024a; Bayer, 2023). Generic manufacturers often use the same functional classes, although supplier grades, concentrations, processing order and coating systems may differ.

How does sorafenib’s solubility affect excipient selection?

Sorafenib tosylate is a poorly water-soluble compound. Its absorption is therefore dependent on particle wetting, dissolution rate, intestinal solubilization and formulation microenvironment. The molecule also has a high dose relative to its solubility, making simple disintegration insufficient as a formulation strategy.

The commercial formulation challenge has four parts:

1. Achieve rapid and reproducible dissolution.
2. Control hydrophobicity caused by the drug substance and lubricant.
3. Maintain tablet strength at a 200 mg active load.
4. Avoid food-dependent exposure variability beyond the reference product.

Sodium lauryl sulfate provides a direct wetting function, while croscarmellose sodium accelerates tablet breakup. Microcrystalline cellulose provides the bulk needed for compression. Magnesium stearate requires process control because over-lubrication can create a hydrophobic tablet surface and reduce dissolution.

A generic formulation does not need to improve clinical exposure over Nexavar. It must match the reference product’s quality and bioequivalence profile. This favors conservative excipient selection for ANDA products and more aggressive solubilization only for products pursuing a differentiated regulatory pathway.

What excipient strategies can improve sorafenib dissolution?

Surfactant-assisted immediate-release tablets

Surfactants such as sodium lauryl sulfate, poloxamers and certain nonionic surfactants can improve wetting and apparent dissolution. Sodium lauryl sulfate is already present in Nexavar, which reduces regulatory and compatibility risk for a conventional generic.

Commercial advantages include:

• Low development cost.
• Compatibility with direct compression or granulation.
• Limited change to the established dosage form.
• Straightforward comparative dissolution testing.

The main risks are excessive foaming, impaired tablet strength, gastrointestinal tolerability and sensitivity to surfactant concentration.

Wet granulation with controlled binder levels

Wet granulation can improve content uniformity and distribute surfactant across the powder bed. Hypromellose or povidone can act as binders, but excessive binder levels may slow disintegration and dissolution.

For sorafenib, wet granulation is most attractive when the drug substance has poor flow, electrostatic behavior or segregation risk. It is less attractive when the product can meet specifications through direct compression, because additional processing raises cost and scale-up risk.

Particle-size reduction

Micronized or controlled-particle-size sorafenib tosylate can increase surface area and improve dissolution. The approach is technically familiar, but it creates control requirements for:

• Particle-size distribution.
• Agglomeration.
• Electrostatic charging.
• Dust containment.
• Blend uniformity.
• Solid-state stability.

Particle-size reduction is usually a strong generic-enabling tool when the API supplier can provide a consistent grade. It may not create meaningful patent differentiation by itself because particle-size specifications can be difficult to protect broadly and may be treated as a manufacturing attribute.

Amorphous solid dispersions

Amorphous solid dispersions using polymers such as hypromellose acetate succinate, hydroxypropyl cellulose, povidone or copovidone can increase apparent solubility. The approach has a stronger technical differentiation profile than a conventional tablet, but it also introduces physical stability and recrystallization risks.

An amorphous dispersion may be commercially appropriate when:

• The product targets a smaller tablet or lower dose burden.
• A new drug application or 505(b)(2) strategy is acceptable.
• A patentable composition-of-matter or process position is available.
• The sponsor can support solid-state characterization and long-term stability.

For a conventional ANDA, the benefit may not justify the added development burden unless the reference dissolution profile is difficult to match.

Lipid-based or self-emulsifying systems

Lipid excipients, medium-chain triglycerides, surfactants and co-solvents can improve solubilization. These systems may be delivered as softgels, capsules or specialized tablets.

The strategy is commercially more differentiated but faces greater regulatory and product-performance risk. Sorafenib’s labeled food effect makes lipid-based delivery particularly sensitive to the relationship between formulation lipids and meal composition. A formulation that produces higher exposure than the reference product could require additional clinical evaluation rather than routine bioequivalence development.

Co-crystals, salts and solid-form engineering

Sorafenib tosylate is already a salt form. Alternative solid forms, co-crystals or modified salt systems may improve manufacturability or dissolution, but they can change the regulatory identity of the active ingredient and create intellectual-property exposure.

This approach is better suited to lifecycle management than a low-cost generic. The value depends on whether the new solid form delivers a measurable clinical or commercial benefit, such as reduced dose frequency, lower variability or improved storage stability.

What formulations are protected by sorafenib patents?

The principal historical Nexavar patent estate included composition and kinase-inhibitor patents covering sorafenib-related chemical matter. The core U.S. composition patent was U.S. Patent No. 6,995,190, assigned to Bayer and related entities, with an expiration date generally reported in 2020 after applicable adjustments and extensions (U.S. Patent No. 6,995,190; FDA, 2024b).

Patent category	Historical relevance	Commercial implication
Sorafenib chemical composition	Covered the active compound and related compounds	Core entry barrier has expired
Pharmaceutical compositions	May cover drug-containing compositions and use formats	Scope depends on claim construction and jurisdiction
Methods of treatment	Covered selected cancer indications or dosing methods	Potential residual risk varies by country
Manufacturing processes	Can protect solid form, synthesis or purification	May remain relevant where separately granted
Formulation improvements	May cover enhanced solubility or delivery systems	Main opportunity for lifecycle products

The original composition patent expiration materially reduced barriers to generic entry. Remaining risks are jurisdiction-specific and depend on granted claims, terminal disclaimers, patent-term adjustments, regulatory exclusivity and litigation history. A product-by-product freedom-to-operate analysis is required before launch.

When did sorafenib lose market exclusivity?

Sorafenib’s principal U.S. small-molecule exclusivity barriers expired in the early 2020s. The core patent protection was generally associated with an expiration around March 2020, subject to patent-term calculations. FDA-approved generic sorafenib products subsequently entered the U.S. market through the ANDA pathway.

Milestone	Approximate timing
FDA approval of Nexavar for renal cell carcinoma	2005
FDA approval for hepatocellular carcinoma	2007
FDA approval for differentiated thyroid carcinoma	2013
Core U.S. patent expiration	2020, subject to applicable adjustments
Generic market development	Early 2020s
Current market structure	Originator plus multiple generic suppliers

The relevant commercial question is no longer whether the original compound is broadly protected. It is whether a supplier can produce a compliant tablet at competitive cost while maintaining supply reliability and acceptable gross margin.

What generic entry risks exist for sorafenib?

Paragraph IV challenges

Sorafenib generics can use an ANDA with a Paragraph IV certification against listed patents that the applicant believes are invalid, unenforceable or not infringed. A Paragraph IV filing can trigger patent litigation and a potential 30-month stay under the Hatch-Waxman framework, depending on the patent and procedural circumstances (FDA, 2024b).

Because the core composition patent has expired, current Paragraph IV risk is more likely to involve:

• Method-of-use patents.
• Later-issued formulation patents.
• Process or solid-form patents.
• Pediatric or jurisdiction-specific rights.
• Patents listed for particular indications or dosage methods.

An ANDA sponsor should separate patent risk into product claims, indication claims and process claims. A formulation change that improves dissolution may create new patent exposure even when it reduces dependence on the original formulation.

Manufacturing and supply risk

The larger operational risks are often non-patent barriers:

• Limited qualified API sources.
• High containment requirements for oncology compounds.
• Nitrosamine or elemental-impurity controls where applicable.
• Coating color consistency.
• Dissolution variability across equipment scales.
• Serialization and global packaging requirements.
• Tender-driven price erosion.

A formulation using commonly available excipients can reduce supply risk, but excipient grade changes may still require comparative dissolution, stability and regulatory documentation.

How strong is the patent estate for sorafenib excipient technologies?

The original sorafenib patent estate is materially weaker than it was before 2020 because the principal active-ingredient protection has expired. Excipient-based opportunities can still support new patents, but claim strength varies.

Excipient strategy	Patentability potential	Regulatory burden	Commercial fit
Conventional SLS-based tablet	Low	Low	ANDA generic
Micronized API with defined dissolution	Moderate	Low to moderate	Generic and regional supply
Amorphous solid dispersion	High	Moderate to high	Lifecycle product
Lipid or self-emulsifying system	Moderate to high	High	Differentiated oral product
Novel coating or taste-masking system	Moderate	Moderate	Specialty or adherence product
Modified-release formulation	High	High	Lifecycle product with clinical risk
Co-crystal or alternative solid form	High	High	505(b)(2) or international lifecycle strategy

The strongest patent positions generally require a defined composition, measurable performance threshold and reproducible manufacturing process. A patent claiming only the use of a known disintegrant or surfactant at routine concentrations is more vulnerable to invalidity and design-around strategies.

What commercial opportunities exist for sorafenib excipients?

Low-cost ANDA supply

The largest accessible opportunity is conventional immediate-release generic supply. Excipients should be selected for:

• Low unit cost.
• Global availability.
• Simple manufacturing.
• Reliable dissolution.
• Minimal change from the reference product.
• Compatibility with multiple API suppliers.

This strategy is most suitable for manufacturers with oncology supply infrastructure, established ANDA capabilities and access to regulated markets.

Regional and tender markets

Sorafenib remains relevant in countries where liver, kidney and thyroid cancers generate demand and where access is driven by government procurement. Commercial success depends on delivered cost, registration coverage, local supply and predictable availability more than on formulation novelty.

A robust formulation should tolerate regional API and excipient sourcing while maintaining dissolution and stability specifications.

Lifecycle management

A differentiated formulation could target:

• Lower pill burden.
• Reduced food effect.
• Improved dissolution in patients with variable gastrointestinal conditions.
• Reduced tablet size.
• Improved swallowability.
• Better adherence.
• Pediatric or geriatric administration.
• Reduced gastrointestinal intolerance.

These opportunities require clinical and regulatory justification. They are not automatic extensions of the generic business.

Contract development and manufacturing

Excipient suppliers and contract manufacturers can capture value by offering:

• Co-processed disintegrant-surfactant systems.
• Controlled-particle-size sorafenib blends.
• Continuous manufacturing platforms.
• Oncology-grade containment and cleaning validation.
• Ready-to-file comparative dissolution packages.
• Film-coating systems with validated color and stability performance.

The commercial proposition is strongest when the excipient platform solves a documented manufacturing or bioequivalence problem rather than offering a generic formulation concept.

How does sorafenib compare with other oral oncology generics?

Product	Main formulation challenge	Excipient opportunity
Sorafenib tosylate	Poor solubility and high daily dose	Wetting, particle size, dispersion and tablet robustness
Sunitinib malate	Salt-form and dose-strength management	Compression, stability and content uniformity
Pazopanib hydrochloride	Poor solubility and food effect	Solubilization and dissolution control
Regorafenib monohydrate	Poor solubility and high dose	Particle engineering and surfactant systems
Imatinib mesylate	More manageable aqueous behavior	Standard compression and stability optimization

Sorafenib has a more direct need for wetting and dissolution control than many oncology tablets. Its 800 mg daily regimen also increases the value of tablet-size reduction, although the reference product’s 200 mg strength limits the amount of active that can be removed from each tablet without changing the dosage form.

What is the FDA regulatory status of sorafenib formulations?

Nexavar is FDA-approved as a prescription tablet. Generic sorafenib products are generally reviewed through the ANDA pathway when they match the reference product in active ingredient, dosage form, strength, route and performance requirements (FDA, 2024a; FDA, 2024b).

A conventional excipient substitution may remain within an ANDA if the product demonstrates pharmaceutical equivalence, bioequivalence, stability and acceptable inactive-ingredient status. A substantially different delivery system, modified release, new dosage form or clinically meaningful pharmacokinetic change may require a 505(b)(2) application or an NDA.

The FDA’s Inactive Ingredient Database can support preliminary excipient selection, but prior use in another product does not by itself establish suitability for sorafenib. Maximum daily exposure, route, dosage form and patient population remain relevant.

Key Takeaways

• Sorafenib tosylate is a high-dose, poorly soluble oral oncology drug.
• Nexavar uses a conventional immediate-release tablet with microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, hypromellose and magnesium stearate.
• The most practical generic strategy is conservative excipient matching combined with controlled wetting, disintegration and lubrication.
• Micronized API and surfactant-assisted granulation offer the best balance between technical value and ANDA feasibility.
• Amorphous dispersions, lipid systems and alternative solid forms offer stronger differentiation but higher regulatory and patent risk.
• The core U.S. composition patent barrier expired around 2020, shifting competition toward cost, quality, supply and regional registration.
• Excipient patents are commercially strongest when tied to a defined composition, measurable dissolution benefit and reproducible process.
• Generic launch risk is concentrated in bioequivalence, manufacturing scale-up, API sourcing, oncology containment and price erosion.
• The most credible lifecycle opportunities are lower pill burden, reduced food sensitivity, improved dissolution and better patient usability.

FAQs

Can sorafenib tosylate be formulated as a capsule instead of a tablet?

Yes, but a capsule would not automatically qualify as therapeutically equivalent to the tablet reference product. The dosage-form change could require additional regulatory work and comparative performance data.

Is sodium lauryl sulfate essential for sorafenib dissolution?

It is not necessarily essential, but the reference formulation uses it as a wetting agent. Replacing it requires evidence that dissolution, bioequivalence, stability and tolerability remain acceptable.

Does sorafenib require an enteric-coated formulation?

No. Nexavar is an immediate-release film-coated tablet. Enteric coating would represent a meaningful formulation change and would require a specific performance rationale.

Can excipients reduce sorafenib’s food effect?

They may reduce formulation-driven variability, but the clinical food effect is a drug-product property. Any claim of reduced food sensitivity would require comparative pharmacokinetic evidence.

Are biosimilar regulations relevant to sorafenib?

No. Sorafenib is a chemically synthesized small molecule, not a biologic. Market entrants generally use the generic-drug framework rather than the biosimilar pathway.

References

Bayer AG. (2023). Nexavar (sorafenib tosylate) prescribing information. U.S. Food and Drug Administration labeling database.

U.S. Food and Drug Administration. (2024a). Nexavar: Prescribing information and FDA-approved labeling. https://www.accessdata.fda.gov

U.S. Food and Drug Administration. (2024b). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

U.S. Patent No. 6,995,190. (2006). Substituted pyridine compounds as Raf kinase inhibitors. U.S. Patent and Trademark Office.

U.S. Food and Drug Administration. (2023). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm